Selecting Anti-Microbial Treatment of Aerobic Vaginitis

Current Infectious Disease Reports

Volumn 17, Issue 5, 2015, Pages 1-7

  Donders, Gilbert G G ^a,b,c   Ruban, Katerina ^a   Bellen, Gert ^a  

^a Femicare vzw   (Belgium)

^b ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^c Regional Hospital H Hart   (Belgium)

Author keywords

Aerobic vaginitis; Bacterial vaginosis; Clindamycin; Corticosteroids; Desquamative inflammatory vaginitis; Dyspareunia; Group B streptococ; Gynoflor; Kanamycin; Leucorrhea; Local estrogen; Metronidazole; Microscopy; Pregnancy complications; Probiotic; Vaginal atrophy; Vaginal immunity; Vaginal inflammation; Vaginal treatment; Wet mount

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIFUNGAL AGENT; CORTICOSTEROID; ESTRIOL; ESTROGEN; KANAMYCIN; MOXIFLOXACIN; POVIDONE IODINE; PROBIOTIC AGENT; STEROID;

AEROBIC VAGINITIS; ANAEROBIC BACTERIUM; ANTIBIOTIC THERAPY; ANTIMICROBIAL THERAPY; BACTERIAL COLONIZATION; BACTERIAL LOAD; BACTERIUM CULTURE; BREAST CANCER; CLINICAL PRACTICE; COMMENSAL; ESCHERICHIA COLI; FOLLOW UP; HUMAN; INFLAMMATION; LOCAL THERAPY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MICROSCOPY; NONHUMAN; PATHOGENESIS; PH; PREGNANCY; REVIEW; STAPHYLOCOCCUS AUREUS; STEROID THERAPY; STREPTOCOCCUS AGALACTIAE; SYSTEMATIC REVIEW; VAGINITIS; VULVITIS;

EID: 84928405807     PISSN: 15233847     EISSN: 15343146     Source Type: Journal    
DOI: 10.1007/s11908-015-0477-6     Document Type: Review

References (64)

1. Donders GG. Definition and classification of abnormal vaginal flora. Best Pract Res Clin Obstet Gynaecol. 2007;21(3):355–73.
2. Donders G. We, specialists in vulvovaginitis. Am J Obstet Gynecol. 2001;184(2):248–9.
3. Donders GG, Vereecken A, Bosmans E, Dekeersmaecker A, Salembier G, Spitz B. Definition of a type of abnormal vaginal flora that is distinct from bacterial vaginosis: aerobic vaginitis. BJOG. 2002;109(1):34–43. This paper describes the original definition of aerobic vaginitis (AV) and provides evidence of inflammation and cytologic abberations that differentiate the condition from the well-known bacterial vaginosis.
4. Gardner HL. Desquamative inflammatory vaginitis: a newly defined entity. Am J Obstet Gynecol. 1968;102(8):1102–5.
5. Murphy R. Desquamative inflammatory vaginitis. Dermatol Ther. 2004;17(1):47–9.
6. Nyirjesy P. Management of persistent vaginitis. Obstet Gynecol. 2014;124(6):1135–46.
7. Oates JK, Rowen D. Desquamative inflammatory vaginitis. A review. Genitourin Med. 1990;66(4):275–9.
8. Reichman O, Sobel J. Desquamative inflammatory vaginitis. Best Pract Res Clin Obstet Gynaecol. 2014;28(7):1042–50.
9. Mirmonsef P, Gilbert D, Zariffard MR, Hamaker BR, Kaur A, Landay AL, et al. The effects of commensal bacteria on innate immune responses in the female genital tract. Am J Reprod Immunol. 2011;65(3):190–5.
10. Cauci S, Driussi S, Guaschino S, Isola M, Quadrifoglio F. Correlation of local interleukin-1beta levels with specific IgA response against Gardnerella vaginalis cytolysin in women with bacterial vaginosis. Am J Reprod Immunol. 2002;47(5):257–64.
11. Mitchell CM, Balkus J, Agnew KJ, Cohn S, Luque A, Lawler R, et al. Bacterial vaginosis, not HIV, is primarily responsible for increased vaginal concentrations of proinflammatory cytokines. AIDS Res Hum Retrovir. 2008;24(5):667–71.
12. Nikolaitchouk N, Andersch B, Falsen E, Strombeck L, Mattsby-Baltzer I. The lower genital tract microbiota in relation to cytokine-, SLPI- and endotoxin levels: application of checkerboard DNA-DNA hybridization (CDH). APMIS. 2008;116(4):263–77.
13. Donders GG, Bosmans E, Dekeersmaecker A, Vereecken A, Van BB, Spitz B. Pathogenesis of abnormal vaginal bacterial flora. Am J Obstet Gynecol. 2000;182(4):872–8.
14. Marconi C, Santos-Greatti MM, Parada CM, Pontes A, Pontes AG, Giraldo PC, et al. Cervicovaginal levels of proinflammatory cytokines are increased during chlamydial infection in bacterial vaginosis but not in lactobacilli-dominated flora. J Low Genit Tract Dis. 2014;18(3):261–5.
15. Briselden AM, Moncla BJ, Stevens CE, Hillier SL. Sialidases (neuraminidases) in bacterial vaginosis and bacterial vaginosis-associated microflora. J Clin Microbiol. 1992;30(3):663–6.
16. Cauci S, Driussi S, Monte R, Lanzafame P, Pitzus E, Quadrifoglio F. Immunoglobulin A response against Gardnerella vaginalis hemolysin and sialidase activity in bacterial vaginosis. Am J Obstet Gynecol. 1998;178(3):511–5.
17. Cauci S, Monte R, Driussi S, Lanzafame P, Quadrifoglio F. Impairment of the mucosal immune system: IgA and IgM cleavage detected in vaginal washings of a subgroup of patients with bacterial vaginosis. J Infect Dis. 1998;178(6):1698–706.
18. Cauci S, Thorsen P, Schendel DE, Bremmelgaard A, Quadrifoglio F, Guaschino S. Determination of immunoglobulin A against Gardnerella vaginalis hemolysin, sialidase, and prolidase activities in vaginal fluid: implications for adverse pregnancy outcomes. J Clin Microbiol. 2003;41(1):435–8.
19. Marconi C, Donders GG, Bellen G, Brown DR, Parada CM, Silva MG. Sialidase activity in aerobic vaginitis is equal to levels during bacterial vaginosis. Eur J Obstet Gynecol Reprod Biol. 2013;167(2):205–9.
20. Marconi C, Donders GG, Martin LF, Ramos BR, Duarte MT, Parada CM, et al. Chlamydial infection in a high risk population: association with vaginal flora patterns. Arch Gynecol Obstet. 2012;285(4):1013–8.
21. Donders GG, Van BB, Van de Walle P, Kaiser RR, Pohlig G, Gonser S, et al. Effect of lyophilized lactobacilli and 0.03 mg estriol (Gynoflor(R)) on vaginitis and vaginosis with disrupted vaginal microflora: a multicenter, randomized, single-blind, active-controlled pilot study. Gynecol Obstet Investig. 2010;70(4):264–72.
22. Donders G, Neven P, Moegele M, Lintermans A, Bellen G, Prasauskas V, et al. Ultra-low-dose estriol and Lactobacillus acidophilus vaginal tablets (Gynoflor((R))) for vaginal atrophy in postmenopausal breast cancer patients on aromatase inhibitors: pharmacokinetic, safety, and efficacy phase I clinical study. Breast Cancer Res Treat. 2014;145(2):371–9.
23. Han C, Wu W, Fan A, Wang Y, Zhang H, Chu Z, et al. Diagnostic and therapeutic advancements for aerobic vaginitis. Arch Gynecol Obstet 2015;291(2):251–7. Perfect state of the art of the current AV treatment possibilities.
24. Haas DM, Morgan S, Contreras K. Vaginal preparation with antiseptic solution before cesarean section for preventing postoperative infections. Cochrane Database Syst Rev. 2013;1, CD007892.
25. Achilles SL, Reeves MF. Prevention of infection after induced abortion: release date October 2010: SFP guideline 20102. Contraception. 2011;83(4):295–309.
26. Tsai YC, Lin MY, Chen SH, Chung MT, Loo TC, Huang KF, et al. Vaginal disinfection with povidone iodine immediately before oocyte retrieval is effective in preventing pelvic abscess formation without compromising the outcome of IVF-ET. J Assist Reprod Genet. 2005;22(4):173–5.
27. Wewalka G, Stary A, Bosse B, Duerr HE, Reimer K. Efficacy of povidone-iodine vaginal suppositories in the treatment of bacterial vaginosis. Dermatology. 2002;204 Suppl 1:79–85.
28. Mumtaz S, Ahmad M, Aftab I, Akhtar N, Ul HM, Hamid A. Aerobic vaginal pathogens and their sensitivity pattern. J Ayub Med Coll Abbottabad. 2008;20(1):113–7.
29. Fan A, Yue Y, Geng N, Zhang H, Wang Y, Xue F. Aerobic vaginitis and mixed infections: comparison of clinical and laboratory findings. Arch Gynecol Obstet. 2013;287(2):329–35.
30. Monif GR. Semiquantitative bacterial observations with group B streptococcal vulvovaginitis. Infect Dis Obstet Gynecol. 1999;7(5):227–9.
31. Cool-Foley AA, Nathan C, O’Donovan III C, Simon D. Eradication of methicillin-resistant Staphylococcus aureus vaginitis with mupirocin. DICP. 1991;25(12):1331–3.
32. Verstraelen H, Verhelst R, Vaneechoutte M, Temmerman M. Group A streptococcal vaginitis: an unrecognized cause of vaginal symptoms in adult women. Arch Gynecol Obstet. 2011;284(1):95–8.
33. van der Meijden WI, Ewing PC. Papular colpitis: a distinct clinical entity? Symptoms, signs, histopathological diagnosis, and treatment in a series of patients seen at the Rotterdam vulvar clinic. J Low Genit Tract Dis. 2011;15(1):60–5.
34. Kasten MJ. Clindamycin, metronidazole, and chloramphenicol. Mayo Clin Proc. 1999;74(8):825–33.
35. Sobel JD. Desquamative inflammatory vaginitis: a new subgroup of purulent vaginitis responsive to topical 2% clindamycin therapy. Am J Obstet Gynecol. 1994;171(5):1215–20.
36. Sobel JD, Reichman O, Misra D, Yoo W. Prognosis and treatment of desquamative inflammatory vaginitis. Obstet Gynecol. 2011;117(4):850–5.
37. Woods CR. Macrolide-inducible resistance to clindamycin and the D-test. Pediatr Infect Dis J. 2009;28(12):1115–8.
38. Sabol KE, Echevarria KL, Lewis JS. Community-associated methicillin-resistant Staphylococcus aureus: new bug, old drugs. Ann Pharmacother. 2006;40(6):1125–33.
39. Lin K, Tierno Jr PM, Komisar A. Increasing antibiotic resistance of streptococcus species in New York City. Laryngoscope. 2004;114(7):1147–50.
40. Tempera G, Furneri PM. Management of aerobic vaginitis. Gynecol Obstet Investig. 2010;70(4):244–9.
41. Tempera G, Abbadessa G, Bonfiglio G, Cammarata E, Cianci A, Corsello S, et al. Topical kanamycin: an effective therapeutic option in aerobic vaginitis. J Chemother. 2006;18(4):409–14. Well designed study testing 2 local treatment options for AV.
42. Tempera G, Bonfiglio G, Cammarata E, Corsello S, Cianci A. Microbiological/clinical characteristics and validation of topical therapy with kanamycin in aerobic vaginitis: a pilot study. Int J Antimicrob Agents. 2004;24(1):85–8.
43. Jaisamrarn U, Triratanachat S, Chaikittisilpa S, Grob P, Prasauskas V, Taechakraichana N. Ultra-low-dose estriol and lactobacilli in the local treatment of postmenopausal vaginal atrophy. Climacteric. 2013;16(3):347–55.
44. Buchholz S, Mogele M, Lintermans A, Bellen G, Prasauskas V, Ortmann O, et al. Vaginal estriol-lactobacilli combination (Gynoflor) therapy and sexual quality of life in aromatase inhibitor-treated breast cancer patients with atrophic vaginitis. Climacteric 2014;1–23. doi:10.3109/13697137.2014.991301.
45. Donders GG, Vereecken A, Bosmans E, Spitz B. Vaginal cytokines in normal pregnancy. Am J Obstet Gynecol. 2003;189(5):1433–8.
46. Donders GG, Van CK, Bellen G, Reybrouck R, Van den Bosch T, Riphagen I, et al. Predictive value for preterm birth of abnormal vaginal flora, bacterial vaginosis and aerobic vaginitis during the first trimester of pregnancy. BJOG. 2009;116(10):1315–24.
47. Curzik D, Drazancic A, Hrgovic Z. Nonspecific aerobic vaginitis and pregnancy. Fetal Diagn Ther. 2001;16(3):187–92.
48. Rezeberga D, Lazdane G, Kroica J, Sokolova L, Donders GG. Placental histological inflammation and reproductive tract infections in a low risk pregnant population in Latvia. Acta Obstet Gynecol Scand. 2008;87(3):360–5.
49. Donders G, Bellen G, Rezeberga D. Aerobic vaginitis in pregnancy. BJOG. 2011;118(10):1163–70.
50. Lamont RF, Nhan-Chang CL, Sobel JD, Workowski K, Conde-Agudelo A, Romero R. Treatment of abnormal vaginal flora in early pregnancy with clindamycin for the prevention of spontaneous preterm birth: a systematic review and metaanalysis. Am J Obstet Gynecol. 2011;205(3):177–90.
51. Kiss H, Petricevic L, Husslein P. Prospective randomised controlled trial of an infection screening programme to reduce the rate of preterm delivery. BMJ. 2004;329(7462):371.
52. Larsson PG, Fahraeus L, Carlsson B, Jakobsson T, Forsum U. Late miscarriage and preterm birth after treatment with clindamycin: a randomised consent design study according to Zelen. BJOG. 2006;113(6):629–37.
53. Lamont RF, Duncan SL, Mandal D, Bassett P. Intravaginal clindamycin to reduce preterm birth in women with abnormal genital tract flora. Obstet Gynecol. 2003;101(3):516–22.
54. Ugwumadu A, Manyonda I, Reid F, Hay P. Effect of early oral clindamycin on late miscarriage and preterm delivery in asymptomatic women with abnormal vaginal flora and bacterial vaginosis: a randomised controlled trial. Lancet. 2003;361(9362):983–8.
55. Kekki M, Kurki T, Pelkonen J, Kurkinen-Raty M, Cacciatore B, Paavonen J. Vaginal clindamycin in preventing preterm birth and peripartal infections in asymptomatic women with bacterial vaginosis: a randomized, controlled trial. Obstet Gynecol. 2001;97(5 Pt 1):643–8.
56. McGregor JA, French JI, Jones W, Milligan K, McKinney PJ, Patterson E, et al. Bacterial vaginosis is associated with prematurity and vaginal fluid mucinase and sialidase: results of a controlled trial of topical clindamycin cream. Am J Obstet Gynecol. 1994;170(4):1048–59.
57. Lamont RF, Taylor-Robinson D, Bassett P. Rescreening for abnormal vaginal flora in pregnancy and re-treating with clindamycin vaginal cream significantly increases cure and improvement rates. Int J STD AIDS. 2012;23(8):565–9.
58. Nenadic DB, Pavlovic MD. Cervical fluid cytokines in pregnant women: relation to vaginal wet mount findings and polymorphonuclear leukocyte counts. Eur J Obstet Gynecol Reprod Biol. 2008;140(2):165–70.
59. Krauss-Silva L, Almada-Horta A, Alves MB, Camacho KG, Moreira ME, Braga A. Basic vaginal pH, bacterial vaginosis and aerobic vaginitis: prevalence in early pregnancy and risk of spontaneous preterm delivery, a prospective study in a low socioeconomic and multiethnic South American population. BMC Pregnancy Childbirth. 2014;14:107.
60. Derbent AU, Ulukanligil M, Keskin EA, Soylu G, Kafali H. Does vaginal irrigation with saline solution in women with infectious vaginitis contribute to the clinical and microbiological results of antibiotic therapy? Gynecol Obstet Investig. 2012;73(3):195–200.
61. Frey TB. Antimicrobial topical agents used in the vagina. Curr Probl Dermatol. 2011;40:36–47.
62. Donders GG, Berger J, Heuninckx H, Bellen G, Cornelis A. Vaginal flora changes on Pap smears after insertion of levonorgestrel-releasing intrauterine device. Contraception. 2011;83(4):352–6.
63. Fan AP, Xue FX. Clinical characteristics of aerobic vaginitis and its mixed infections. Zhonghua Fu Chan Ke Za Zhi. 2010;45(12):904–8.
64. Cepicky P, Malina J, Libalova Z, Kuzelova M. “Mixed” and “miscellaneous” vulvovaginitis: diagnostics and therapy of vaginal administration of nystatin and nifuratel. Ceska Gynekol. 2005;70(3):232–7.